FDA con­verts ac­cel­er­at­ed to full ap­proval for Pad­cev-Keytru­da com­bo in blad­der can­cer

The FDA on Fri­day grant­ed full ap­proval to Seagen and Astel­las Phar­ma’s Pad­cev (en­for­tum­ab ve­dotin-ejfv) in com­bo with Mer­ck’s Keytru­da (pem­brolizum­ab) for pa­tients with lo­cal­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER